[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619816":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":36,"locations":42,"responsibleParty":175,"collaborators":28,"id":177,"slug":178,"hasResults":179,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":28,"eligibilityCriteria":183,"healthyVolunteers":179,"sex":184,"minAge":185,"maxAge":28,"enrollmentInfo":186,"targetDuration":28,"studyType":189,"phases":190,"briefSummary":192,"conditions":193,"keywords":204,"overallStatus":45,"whyStopped":28,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},{"fullName":5,"class":6},"Revolution Medicines, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: RMC-5127 Monotherapy","EXPERIMENTAL","Dose Escalation and Dose Expansion",[13],"Drug: RMC-5127",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm B: RMC-5127 + Daraxonrasib Combination",[13,17],"Drug: daraxonrasib",{"label":19,"type":10,"description":11,"interventionNames":20},"Arm C: RMC-5127 + Cetuximab Combination",[13,21],"Drug: cetuximab",[23,29,32],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","RMC-5127","oral tablets",[9,15,19],null,{"type":24,"name":30,"description":26,"armGroupLabels":31,"otherNames":28},"daraxonrasib",[15],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":28},"cetuximab","IV infusion",[19],[37],{"name":38,"role":39,"phone":40,"phoneExt":28,"email":41},"Revolution Medicines Study Director","CONTACT","1-844-2-REVMED","medinfo@revmed.com",[43,62,77,92,107,121,136,150,160],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Yale Cancer Center","RECRUITING","New Haven","Connecticut","06511","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-72.92816,41.30815,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":28,"email":61},"Ingrid Palma","203-833-1034","ingrid.palma@yale.edu",{"facility":63,"status":45,"city":64,"state":65,"zip":66,"country":49,"countryCode":50,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Johns Hopkins","Baltimore","Maryland","21231",{"type":52,"coordinates":68},[69,70],-76.61219,39.29038,{"lat":70,"lon":69},[73],{"name":74,"role":39,"phone":75,"phoneExt":28,"email":76},"Katelyn Spence","443-927-1685","kspenc29@jh.edu",{"facility":78,"status":45,"city":79,"state":80,"zip":81,"country":49,"countryCode":50,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":52,"coordinates":83},[84,85],-71.05977,42.35843,{"lat":85,"lon":84},[88],{"name":89,"role":39,"phone":90,"phoneExt":28,"email":91},"Kailene Sullivan","617-632-3482","kailene_sullivan@dfci.harvard.edu",{"facility":93,"status":45,"city":94,"state":95,"zip":96,"country":49,"countryCode":50,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"START Midwest","Grand Rapids","Michigan","49546",{"type":52,"coordinates":98},[99,100],-85.66809,42.96336,{"lat":100,"lon":99},[103],{"name":28,"role":39,"phone":104,"phoneExt":105,"email":106},"616-954-5554","ext. 4","hopeteam@startresearch.com",{"facility":108,"status":45,"city":109,"state":109,"zip":110,"country":49,"countryCode":50,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","New York","10016",{"type":52,"coordinates":112},[113,114],-74.00597,40.71427,{"lat":114,"lon":113},[117],{"name":118,"role":39,"phone":119,"phoneExt":28,"email":120},"Salman Punekar","212-731-6228","salman.punekar@nyulangone.org",{"facility":122,"status":45,"city":123,"state":124,"zip":125,"country":49,"countryCode":50,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"NEXT - Dallas","Dallas","Texas","75039",{"type":52,"coordinates":127},[128,129],-96.80667,32.78306,{"lat":129,"lon":128},[132],{"name":133,"role":39,"phone":134,"phoneExt":28,"email":135},"NEXT TXReferrels","972-893-8800","NXT_TXReferrals@nextoncology.com",{"facility":137,"status":45,"city":138,"state":124,"zip":139,"country":49,"countryCode":50,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"NEXT","San Antonio","78229",{"type":52,"coordinates":141},[142,143],-98.49363,29.42412,{"lat":143,"lon":142},[146],{"name":147,"role":39,"phone":148,"phoneExt":28,"email":149},"Jordan Georg","210-580-9521","jgeorg@nextoncology.com",{"facility":151,"status":45,"city":138,"state":124,"zip":139,"country":49,"countryCode":50,"cosmosGeoPoint":152,"geoPoint":154,"contacts":155},"START - San Antonio",{"type":52,"coordinates":153},[142,143],{"lat":143,"lon":142},[156],{"name":157,"role":39,"phone":158,"phoneExt":28,"email":159},"Isabel Jimenez","210-593-5265","isabel.jimenez@startresearch.com",{"facility":161,"status":45,"city":162,"state":163,"zip":164,"country":49,"countryCode":50,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"NEXT - Virginia","Fairfax","Virginia","22031",{"type":52,"coordinates":166},[167,168],-77.30637,38.84622,{"lat":168,"lon":167},[171],{"name":172,"role":39,"phone":173,"phoneExt":28,"email":174},"Paolo Umayam","703-783-4546","pumayam@nextoncology.com",{"type":176,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100619816","phase-1-study-of-rmc-5127-in-patients-with-advanced-kras-g12v-mutant-solid-tumors-100619816",false,"NCT07349537","Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","Phase 1\u002F1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.\n* Measurable per RECIST v1.1\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors\n* Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and\u002For inhibitors).\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to receiving study drug(s).\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.","ALL","18 Years",{"count":187,"type":188},574,"ESTIMATED","INTERVENTIONAL",[191],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.",[194,195,196,197,198,199,200,201,202,203],"Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","PDAC","CRC","NSCLC","Pancreatic Cancer","Lung Cancer (NSCLC)","Advanced Solid Tumors",[203,201,205,198,206,199,207,208,200,209,210,211],"Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","Lung Cancer","Non-small Cell Lung Cancer","RAS","KRAS","RAS Mutation","2026-07-08",{"date":214,"type":215},"2026-07-10","ACTUAL",{"date":217,"type":215},"2026-01-08",{"date":219,"type":188},"2028-10",{"name":5,"class":6},9]